Professor of Pediatrics, Section of Pediatric Endocrinology & Metabolism, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226.===Search for more papers by this author

Hanaa Zidan MD,

Hanaa Zidan MD

Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

Search for more papers by this author

Stanley Lo PhD,

Stanley Lo PhD

Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin

Search for more papers by this author

Donald Wiebe PhD,

Donald Wiebe PhD

Department of Pathology & Laboratory Medicine, University of Wisconsin, Madison, Wisconsin

Search for more papers by this author

Julie Talano MD,

Julie Talano MD

Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

Search for more papers by this author

Ramin Alemzadeh MD,

Corresponding Author

Ramin Alemzadeh MD

[email protected]

Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

Professor of Pediatrics, Section of Pediatric Endocrinology & Metabolism, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226.===Search for more papers by this author

First published: 19 February 2008

https://doi.org/10.1002/pbc.21522

Citations: 16

Share a link

Email
Wechat
Bluesky

Abstract

We describe a case of extreme hypercholesterolemia, mediated by lipoprotein X, in a 12-year-old Caucasian female who underwent an unrelated allogenic bone marrow transplant for relapsed acute myelocytic leukemia (AML). Her post-transplant course was complicated by severe chronic graft-versus-host disease (GVHD) of the liver. Previously normal serum cholesterol and triglycerides rose to 1,122 mg/dl (29.0 mmol/L) and 1,100 mg/dl (12.4 mmol/L), respectively. Serum cholesterol appeared to be dominantly carried by lipoprotein X. Intra-hepatic cholestasis leading to reflux of bile lipoproteins into the blood stream and subsequent formation of lipoprotein X appears to be the mechanism underlying this phenomenon. Pediatr Blood Cancer 2008;50:1280–1281. © 2008 Wiley-Liss, Inc.

REFERENCES

1 Sprecher DL, Schaefer EJ, Kent KM, et al. Cardiovascular features of homozygous familial hypercholesterolemia: Analysis of 16 patients. Am J Cardiol 1984; 54: 20–30.
10.1016/0002-9149(84)90298-4
CAS PubMed Web of Science® Google Scholar
2 Connelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 1998; 35: 547–572.
10.1080/10408369891234273
CAS PubMed Web of Science® Google Scholar
3 McIntyre N, Harry DS, Pearson AJG. The hypercholesterolemia of obstructive jaundice. Gut 1975; 16: 379–391.
10.1136/gut.16.5.379
CAS PubMed Web of Science® Google Scholar
4 Dickson ER, Fleming CR, Ludwig J. Primary biliary cirrhosis. In: H Popper, F Schaffner, editors. Progress in liver diseases, Vol. 6. New York: Grune & Stratton; 1979. pp. 487–528.
Google Scholar
5 Coetzee GA, van der Westhuyzen DR, Berger GM, et al. Low-density lipoprotein metabolism in cultured fibroblasts from a new group of patients presenting clinically with homozygous familial hypercholesterolemia. Arteriosclerosis 1982; 2: 303–311.
10.1161/01.ATV.2.4.303
CAS PubMed Web of Science® Google Scholar
6 Rosenson RS, Baker AL, Chow MJ, et al. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology 1990; 98: 1351–1357.
10.1016/0016-5085(90)90356-6
CAS PubMed Web of Science® Google Scholar
7 Toren A, Nagler A. Solitary pulmonary cholesteroloma, multiple xanthelasmas, lipemia retinalis complicating hypercholesterolemia after bone marrow transplantation. Bone Marrow Transplant 1996; 18: 457–459.
CAS PubMed Web of Science® Google Scholar
8 Illingworth DR. How effective is drug therapy in heterozygous familial hypercholesterolemia? Am J Cardiol 1993; 72: 54D–58D.
10.1016/0002-9149(93)90011-Z
CAS PubMed Web of Science® Google Scholar
9 Malloy MJ, Kane JP, Kunitake ST, et al. Complementarity of colestipol, niacin, lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 1987; 107: 616–623.
10.7326/0003-4819-107-5-616
CAS PubMed Web of Science® Google Scholar
10 Gordon BR, Kelsey SF, Bilheimer DW, et al. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. Am J Cardiol 1992; 70: 1010–1016.
10.1016/0002-9149(92)90352-Y
CAS PubMed Web of Science® Google Scholar
11 Neudorf S, Sanders J, Kobrinsky N, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 2004; 103: 3655–3661.
10.1182/blood-2003-08-2705
CAS PubMed Web of Science® Google Scholar
12 Coakley JC, Vervaart PP, McKay MRG. Factitious hyponatremia in a patient with cholestatic jaundice following bone marrow transplantation. Pathology 1986; 18: 158–159.
10.3109/00313028609090846
CAS PubMed Web of Science® Google Scholar
13 Turrchin A, Wiebe DA, Seely EW, et al. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of liver. Bone Marrow Transplant 2005; 35: 85–89.
10.1038/sj.bmt.1704739
CAS PubMed Web of Science® Google Scholar
14 Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994; 57: 1479–1483.
10.1097/00007890-199405270-00014
CAS PubMed Web of Science® Google Scholar
15 Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998; 65: 446–449.
10.1097/00007890-199802150-00030
CAS PubMed Web of Science® Google Scholar
16 Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus, cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375–382.
10.1097/01.TP.0000074310.40484.94
CAS PubMed Web of Science® Google Scholar
17 Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170–1180.
CAS PubMed Web of Science® Google Scholar
18 Roche Laboratories. Cellcept® (mycophenolate mofetil) Complete Product Information (online), 2004 (cited October14, 2004). Available from http://www.rochusa.com/products/cellcept/pi.pdf.
Google Scholar
19 Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16: 505–511.
CAS PubMed Web of Science® Google Scholar
20 O'Brien T, Dinneen SF, O'Brien PC, et al. Hyperlipidemia in patients with primary, secondary hypothyroidism. Mayo Clin Proc 1993; 68: 860–866.
10.1016/S0025-6196(12)60694-6
CAS PubMed Web of Science® Google Scholar
21 Glomset JA, Nichols AV, Norum KR, et al. Plasma lipoproteins in familial lecithin-cholesterol acyltransferase deficiency. J Clin Invest 1973; 52: 1078–1092.
10.1172/JCI107273
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume50, Issue6

June 2008

Pages 1280-1281

Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft-versus-host disease of the liver

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft-versus-host disease of the liver

Abstract

REFERENCES

Citing Literature

References

Related

Information